Clinical Trial Search

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Objective Response Rate — 2; 4; 6; 17 Participants

Primary: Percentage of Participants With Response — 34.7 percentage of participants

Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694

Primary: Complete Remission — 10 participants

Primary: Objective Overall Response Rate — 14; 0 participants — p=0.022

Primary: Progression-free Survival — 89 percentage of participants

Primary: Percentage of Patients With Complete Response to the Combination Chemotherapy — 75.0; 23.0 Percentage of participants

Primary: 3 Years Event-free Survival — 51; 56; 126; 123 Participants

Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants

Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005

Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants

Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants

Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria) — 25; 23; 40; 100 percentage of participants

Primary: Assess Number of Patients Who Achieve Confirmed and Unconfirmed Complete Response (CR) or Partial Response (PR) — 0; 0; 0; 20 participants

Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion

Primary: Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3 — 61.1; 63.0; 70.0 Percent of Participants

Primary: Progression-free Survival at 2 Years — 76; 80 percentage of participants — p=0.11

Primary: Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR) — 22.0 Percentage of participants

Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants

Primary: 2-year Overall Survival Rates — 71.1; 73.7 percentage of participants

Primary: Clinical Response Rate — 1; 7; 0; 8 Participants

Primary: Complete Response Rate — 34 Participants

Primary: Complete Response (CR) and Complete Response Unconfirmed (CRu) — 20.0; 5.7; 24.3; 7.1 percentage of randomized patients